<DOC>
	<DOC>NCT02424682</DOC>
	<brief_summary>This study was designed to evaluate safety and tolerability of Herceptin as treatment for patients with human epidermal growth factor receptor 2 (HER-2) positive metastatic breast cancer. Frequency, characteristics and severity of adverse events (AE) and serious adverse events (SAE) were followed to evaluate the safety of Herceptin in patients with HER2 positive metastatic breast cancer.</brief_summary>
	<brief_title>Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Confirmed diagnosis of metastatic breast cancer (BC) with HER2neu overexpression Left Ventricular Ejection Fraction (LVEF) by ECHO or Multi Gated Acquisition Scan (MUGA) &gt; 50% Good performance status: Eastern Cooperative Oncology Group (ECOG) scale &lt; or = 2 and life expectancy &gt; or = 12 weeks Advanced pulmonary disease and severe dyspnea Abnormal laboratory within 14 days prior to registration Peripheral neuropathy &gt; grade 2 Presence of central nervous system (CNS) metastasis Pregnancy or lactating</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>